ID
Post-Covid Long-Term Effects
search
Post-Covid Long-Term Effects
, Long COVID, COVID Long Hauler, Postacute Sequelae of COVID-19, PASC
See Also
Covid19
Epidemiology
Incidence
Adult: 10% of Covid Patients (up to 19 to 30% in some studies)
Child: 8% (e.g. persistent
Fatigue
)
Pathophysiology
Although there are many
Chronic Complications of ICU Care
, Post-Covid effects are often seen in less severe cases
Proposed Mechanisms
Residual tissue injury from acute infection
Persistent smoldering viral activity from a host reservoir
Hyperinflammatory state complications (
Multisystem Inflammatory Syndrome
)
Immune dysfunction
Preexisting comorbid conditions that are unmasked or provoked by Covid infection
Risk Factors
Age over 50 years old
Female gender
Obesity
Severe acute infection (or more than 5 symptoms in the first week of illness)
Unvaccinated or incompletely vaccinated with Covid19
Vaccine
(<3
Vaccine
doses)
Type 2 Diabetes Mellitus
Immunocompromised
patient
Hypertension
Psychiatric Conditions
Earlier strains of Covid
Azzolini (2022) JAMA 328(7): 676-8 [PubMed]
Symptoms
Gene
ral
Fatigue
(<58%)
Similar to
Chronic Fatigue Syndrome
Common in post-covid symptoms >6 months
Night Sweats
(<24%)
Appetite change (<17%)
Weight loss (<21%)
Cardiopulmonary
Chest Pain
(<16%)
Palpitation
s (<14%)
Dyspnea
(<30%)
Cough
(<15%)
Autonomic Dysfunction
(e.g.
Postural Orthostatic Tachycardia Syndrome
or
POTS Syndrome
)
POTS Syndrome
demonstrates
Orthostatic Intolerance
with
Tachycardia
, without significant
Orthostatic Hypotension
Mast Cell
Activation Syndrome (
Hypotension
,
Palpitation
s,
Urticaria
,
Wheezing
,
Rhinitis
,
Pharyngitis
,
Conjunctivitis
)
Decreased
Exercise
tolerance (<15%)
Post-exertional malaise
Common, hallmark symptom in post-covid symptoms >6 months
Exhaustion and prolonged recovery, requiring days to weeks, starting 12 to 72 hours after activity
Musculoskeletal
Decreased mobility (<20%)
Arthralgia
s and myalgias (<14%)
Neurologic
Headache
(12 to 44%)
Cognitive dysfunction (common in post-covid symptoms >6 months)
Attention disorder, difficulty concentrating or brain fog (<27%)
Memory deficit (<19%)
Altered taste,
Ageusia
, parageusia, dysguesia (<23%)
Altered
Sense of Smell
,
Anosmia
or
Parosmia
(<21%)
Otte (2020) J Infect 81(3):e58 +PMID: 32592702 [PubMed]
Skin
Alopecia
(<25%)
Psychiatric
Anxiety (<30%)
Depression (<23%)
Post-Traumatic Stress Disorder
(<13%)
Insomnia
or other sleep disorder (<27%)
Associated Conditions
Respiratory
DLCO
Decreased on
Pulmonary Function Test
ing
Decreased lower respiratory
Muscle Strength
Persistently abnormal CT
Chest
Huang (2020) Respir Res 21(1):163 +PMID: 32600344 [PubMed]
Lerum TV (2020) Eur Respir J +PMID: 33303540 [PubMed]
Cardiovascular
Persistent
Myocarditis
Puntmann (2020) JAMA Cardiol 5(11):1265-73 [PubMed]
Rajpal (2021) JAMA Cardiol 6(1):116-8 [PubMed]
Labs
Gene
ral Testing in Most Cases (Identify Reversible Causes)
Complete Blood Count
Comprehensive Metabolic Panel
Serum Magnesium
C-Reactive Protein
Erythrocyte Sedimentation Rate
(ESR)
Serum Ferritin
Thyroid Stimulating Hormone
(TSH)
Serum
Vitamin D
Serum
Vitamin B12
Autonomic Dysfunction
Additional Testing (e.g.
POTS Syndrome
)
Orthostatic Blood Pressure
and pulse
Electrocardiogram
(EKG)
Consider
Gluten Sensitive Enteropathy
testing
Consider
Echocardiogram
Consider autonomic reflex testing
Consider ambulatory
Heart Rate
monitoring (e.g. zio monitor)
Neurocognitive Additional Testing (e.g. Brain Fog)
See
Cognitive Impairment
Cognitive assessment tools (e.g.
Montreal Cognitive Assessment
)
Consider
Neuropsychological Testing
Consider
Thiamine
replacement
Consider
MRI Brain
Dyspnea
Additional Testing
Chest XRay
B-Type Natriuretic Peptide
(BNP)
Pulmonary Function Test
s
Electrocardiogram
(EKG)
Consider
D-Dimer
Consider CT
Chest
Consider
Sleep Study
for
Obstructive Sleep Apnea
(if suspected by history)
Consider
Echocardiogram
Consider home
Pulse Oximetry
Consider
Cortisol
Chronic
Fatigue
Additional Testing
Functional Capacity Testing
Consider Respiratory Additional Testing as above
Consider
Antinuclear Antibody
testing
Mast Cell
Activation Additional Testing (
Hypotension
,
Palpitation
s,
Urticaria
,
Wheezing
,
Rhinitis
,
Pharyngitis
,
Conjunctivitis
)
Serum Tryptase (baseline and within <4 hours of symptom onset)
N-Methylhistamine
24 hour Urine Collection
Prostaglandin
D2
24 hour Urine Collection
Differential Diagnosis
Chronic Complications of ICU Care
(or prolonged illness or hospitalization)
New illness
Exacerbation of comorbid conditions
Chronic Kidney Disease
Diabetes Mellitus
Chronic lung disease (e.g.
Asthma
,
COPD
)
Cardiomyopathy
(e.g. CHF)
Mood Disorder
s (e.g.
Major Depression
,
Anxiety Disorder
)
Altered Smell or Taste
See
Smell Dysfunction
See
Taste Dysfunction
Allergic Rhinitis
Sinusitis
Dyspnea
See
Dyspnea Causes
Obstructive Lung Disease
(
Asthma
,
COPD
)
Restrictive Lung Disease
(e.g. pulmonary fibrosis)
Cardiomyopathy
(e.g.
Congestive Heart Failure
,
Myocarditis
)
Pneumonia
Coronary Artery Disease
Pulmonary Embolism
Anemia
Autonomic Dysfunction
(
Dysautonomia
)
See
Autonomic Dysfunction
POTS Syndrome
Hyperthyroidism
Cardiac Arrhythmia
Inappropriate Sinus Tachycardia
Mast Cell
Activation Syndrome (
Hypotension
,
Palpitation
s,
Urticaria
,
Wheezing
,
Rhinitis
,
Pharyngitis
,
Conjunctivitis
)
POTS Syndrome
Multisystem Inflammatory Syndrome
Diabetes Mellitus
Porphyria
Celiac Disease
Vasculitis
Cognitive Dysfunction
See
Dementia Differential Diagnosis
Cerebrovascular Accident
Multiple Sclerosis
Sleep
Disorder (e.g.
Obstructive Sleep Apnea
)
Major Depression
Traumatic Brain Injury
Chronic Fatigue Syndrome
See
Fatigue Differential Diagnosis
Diagnosis
New, recurrent or ongoing
Covid19
symptoms persisting >28 days (per CDC) or >2 months (WHO)
Covid19
diagnosis may be a clinical diagnosis despite negative PCR or other testing
Of those with known
Covid19
infection, 10-20% will have subsequent negative
Antibody
testing
Management
Gene
ral
Goals of management is improved function and quality of life
Lifestyle Interventions (non-medication therapy)
Limit
Alcohol
and
Caffeine
Tobacco Cessation
Insomnia Nonpharmacologic Management
Meditation and
Mindfulness
Exercise
s
Multi-specialty support
Support groups
Physical Therapy
Specialists (cardiology, pulmonology, ent) as needed
Follow-up every 2-3 months
Altered Smell or Taste
See
Smell Dysfunction
See
Taste Dysfunction
Smell Training
No treatment (e.g.
Intranasal Steroid
s) found effective in speeding olfactory recovery
Improves or resolves more quickly than other causes of
Olfactory Dysfunction
Resolution by 7 days in a majority of patients and by 3 months in 80%
Course prolonged in more severe disease
Ferrell (2022) Eur Arch Otorhinolaryngol 279(9): 4633-40 [PubMed]
Autonomic Dysfunction
(
Dysautonomia
)
See
Autonomic Dysfunction
Eat smaller, more frequent meals
Increase volume status
Consider increased dietary salt when appropriate
Consider
Compression Stockings
Sleep
with head of bed elevated
Perform
Isometric Exercise
s
Avoid triggers of
Orthostatic Intolerance
(e.g. excessive heat,
Alcohol
)
Consider medication management starting at low dose and titrating as needed (e.g.
Propranolol
,
Fludrocortisone
,
Midodrine
)
Local expert
Consultation
recommended
Cognitive dysfunction
Neuropsychiatric
Consultation
Eliminate contributing factors (e.g.
Polypharmacy
, medications impacting attention)
Ensure adequate sleep
Consider neurology
Consultation
Consider occupational therapy
Consider speech pathologist
Gradual return to cognitive activities
Dyspnea
Pulmonary Rehabilitation
and breathing
Exercise
s
Gradual return to activity
Chronic Fatigue Syndrome
Lifestyle changes (adequate sleep,
Healthy Diet
, adequate hydration)
Energy conservation (e.g. 4Ps - Plan, Pace, Prioritize, Position)
Avoid relapse triggers (emotional stress, strenuous activity)
Gradual return to activity
Mast Cell
Activation Syndrome (
Hypotension
,
Palpitation
s,
Urticaria
,
Wheezing
,
Rhinitis
,
Pharyngitis
,
Conjunctivitis
)
Cromolyn
or
Mast Cell Stabilizer
s
Antihistamine
s
Prognosis
Symptom peak timing may predict duration
Recovery by 90 days: Symptoms peak at 2 weeks
Not recovered by 90 days: Symptoms peak at 2 months
Relapses after 6 months (
Fatigue
, post-exertional malaise, cognitive dysfunction) have common triggers
Physical Activity
or
Exercise
Emotional stress
Cognitive activity
Patients should expect continued gradual improvement with periodic relapses and set backs
Outcomes vary from patient to patient and longterm data is limited
More than half of patients will have symptoms >6 months, but these symptoms decrease over time
Most patients with persistent
Dyspnea
following covid improve without chronic lung disease
Most patients recover from
Cognitive Impairment
Prevention
Covid-19 Vaccine
Most effective prevention of Long COVID (pre-exposure)
COVID-19
Treatment
Paxlovid
started within 5 days of Covid onset may reduce the risk of developing Long COVID
Resources
Post-Covid (CDC)
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
SurvivorCorps
https://www.survivorcorps.com/
References
(2023) Presc Lett 30(4): 20-1
Alkodaymi (2022) Clin Microbiol Infect 28(5): 657-66 [PubMed]
Fernandez (2021) Sao Paulo Med. J. 139 +PMID:33656121 [PubMed]
Herman (2022) Am Fam Physician 106(5): 523-32 [PubMed]
Lopez-Leon (2021) medRxiv +PMID: 33532785 [PubMed]
Sneller (2022) Ann Intern Med 175(7): 969-79 [PubMed]
Michelen (2021) BMJ Glob Health 6(9): e005427 [PubMed]
Type your search phrase here